1. Goodman, SM, Cronstein, BN, Bykerk, VP. Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review. Clin Exp Rheumatol. 2015;33(2):272-278.
Google Scholar | Medline2. NHMJ . Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res. 2010;2:293-301. doi:10.2147/CMR.S10043.
Google Scholar | Crossref | Medline3. Berthelot, JM, Maugars, Y, Hamidou, M, et al. Pancytopenia and severe cytopenia induced by low-dose methotrexate. Rev Rhum Engl Ed. 1995;62(7-8):477-486.
Google Scholar | Medline4. Howard, SC, McCormick, J, Pui, C, Buddington, RK, Harvey, RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471-1482. doi:10.1634/theoncologist.2015-0164.
Google Scholar | Crossref | Medline5. Svanström, H, Lund, M, Melbye, M, Pasternak, B. Concomitant use of low-dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis. Pharmacoepidemiol Drug Saf. 2018;27(8):885-893. doi:10.1002/pds.4555.
Google Scholar | Crossref | Medline6. Mori, S, Hidaka, M, Kawakita, T, et al. Factors associated with myelosuppression related to low-dose methotrexate therapy for inflammatory rheumatic diseases. PLoS One. 2016;11(4). doi:10.1371/journal.pone.0154744.
Google Scholar | Crossref7. Mitsuboshi, S. Risk of haematological events and preventive effect of folic acid in methotrexate users with chronic kidney disease and rheumatoid arthritis: analysis of the Japanese Adverse Drug Event Report database. Br J Clin Pharmacol. 2021;87(5):2286-2289. doi:10.1111/bcp.14641.
Google Scholar | Crossref | Medline8. Bourré-Tessier, J, Haraoui, B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol. 2010;37(7):1416-1421. doi:10.3899/jrheum.090153.
Google Scholar | Crossref | Medline9. Ivanyuk, A, Livio, F, Biollaz, J, Buclin, T. Renal drug transporters and drug interactions. Clin Pharmacokinet. 2017;56(8):825-892. doi:10.1007/s40262-017-0506-8.
Google Scholar | Crossref | Medline10. Hira, D, Terada, T. BCRP/ABCG2 and high-alert medications: biochemical, pharmacokinetic, pharmacogenetic, and clinical implications. Biochem Pharmacol. 2018;147:201-210. doi:10.1016/j.bcp.2017.10.004.
Google Scholar | Crossref | Medline11. FitzGerald, JD, Dalbeth, N, Mikuls, T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res. 2020;72(6):744-760. doi:10.1002/acr.24180
Google Scholar | Crossref12. Spina, M, Nagy, Z, Ribera, JM, et al. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015;26(10):2155-2161. doi:10.1093/annonc/mdv317.
Google Scholar | Crossref | Medline13. Chen, CC, Chen, CC, Chang, CJ, et al. Hypersensitivity and cardiovascular risks related to allopurinol and febuxostat therapy in Asians: a population-based cohort study and meta-analysis. Clin Pharmacol Ther. 2019;106(2):391-401. doi:10.1002/cpt.1377.
Google Scholar | Crossref | Medline14. Lehtisalo, M, Keskitalo, JE, Tornio, A, et al. Febuxostat, but not allopurinol, markedly raises the plasma concentrations of the breast cancer resistance protein substrate rosuvastatin. Clin Transl Sci. 2020;13(6):1236-1243. doi:10.1111/cts.12809.
Google Scholar | Crossref | Medline15. Miyata, H, Takada, T, Toyoda, Y, Matsuo, H, Ichida, K, Suzuki, H. Identification of febuxostat as a new strong ABCG2 inhibitor: potential applications and risks in clinical situations. Front Pharmacol. 2016;7:518. doi:10.3389/fphar.2016.00518.
Google Scholar | Crossref | Medline16. Ikemura, K, Hiramatsu, S, ichi Shinogi, Y, et al. Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein. Sci Rep. 2019;9(1):20359. doi:10.1038/s41598-019-56900-2.
Google Scholar | Crossref | Medline17. Kanbayashi, Y, Nomura, K, Okamoto, K, et al. Statistical examination to determine whether only 48-h value for serum concentration during high-dose methotrexate therapy is a predictor for clinical adverse events using ordered logistic regression analysis. Ann Hematol. 2010;89(10):965-969. doi:10.1007/s00277-010-0965-6.
Google Scholar | Crossref | Medline18. Schmiegelow, K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol. 2009;146(5):489-503. doi:10.1111/j.1365-2141.2009.07765.x.
Google Scholar | Crossref | Medline19. Bannwarth, B, Péhourcq, F, Schaeverbeke, T, Dehais, J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet. 1996;30(3):194-210. doi:10.2165/00003088-199630030-00002.
Google Scholar | Crossref | Medline20. Wilkinson, DG. Allopurinol and agranulocytosis. Lancet. 1977;2(8051):1282-1283. doi:10.1016/S0140-6736(77)92683-6.
Google Scholar | Crossref | Medline21. Fleischmann, R. Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis. Expert Opin Drug Saf. 2003;2(4):347-365. doi:10.1517/14740338.2.4.347.
Google Scholar | Crossref | Medline22. Strang, A, Pullar, T. Methotrexate toxicity induced by acute renal failure. J R Soc Med. 2004;97(11):536-537. doi:10.1258/jrsm.97.11.536.
Google Scholar | SAGE Journals | ISI